Oncolytics Biotech Inc T.ONC

exel panc phase 3 study stopped and unblinded early

[itntdf]

ALAMEDA, Calif., August 24, 2023--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was observed at an interim analysis. CABINET is evaluating cabozantinib (CABOMETYX®) compared with placebo in patients with either advanced pancreatic neuroendocrine tumors (pNET) or advanced extra-pancreatic neuroendocrine tumors (also referred to as carcinoid tumors) who experienced progression after prior systemic therapy. Cabozantinib substantially prolonged the time without disease progression or death in both of the trial’s cohorts. CABINET is sponsored by the National Cancer Institute (NCI) and is led by The Alliance for Clinical Trials in Oncology. Detailed findings will be presented at an upcoming medical meeting and discussed with the U.S. Food and Drug Administration (FDA).

[itntdf]

"As there is no standard of care for patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors whose disease has progressed after prior therapy, we are pleased to see that cabozantinib improved outcomes for two additional patient populations living with advanced, difficult-to-treat cancers," said Will Berg, M.D., Senior Vice President, Medical Affairs, Exelixis. "

[Snowdrift]

I know Palareopep will soon be moving to a phase 3 study for pancreatic cancer.  Exelixis has just had dynamite results for patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors. All this is way over my head, so let me ask : Is Pela also addressing pancreatic & extrapancreatic neuroendocrine tumors?  If so, does this mean we just lost the race?

[Noteable]

No. Pancreatic neuroendocrine tumors (pNETs) are relatively rare tumors comprising 1-2% of all pancreas neoplasms. Conversely, ONCY =  treatment for first-line metastatic pancreatic ductal adenocarcinoma (PDAC).   Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive lethal malignancy due to the lack of early diagnosis and limited response to treatments. It

[Noteable]

Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage.

[Snowdrift]

Thanks so much for clarifying that, Notable!

[itntdf]

believe notable addressed part of your questions.  my point in posting this was to pony onto some of notable's recent posts addressing the pathway forward and the possibility of outstanding results in an area where there are few to none options for treatment that oncy could advance one of their fast tracks without the need to finish a phase 3. we certainly have not lost the race and at

[Snowdrift]

Now I can see why you posted that information.  It really does confirm Notable's claim that companies can get leap forward without the need to get to the finish line with Phase 3 testing. Fingers crossed.

[Noteable]

EXEL  Market Cap (intraday) US$ 6.92 Billion